Regression of cervical carcinoma in situ following aureomycin.
D002277:Carcinoma; D002278:Carcinoma in Situ; D002294:Carcinoma, Squamous Cell; D002584:Cervix Uteri; D002751:Chlortetracycline / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009369:Neoplasms; D002583:Uterine Cervical Neoplasms
D002751:Chlortetracycline
AUREOMYCIN/therapeutic use; CARCINOMA, EPIDERMOID; CERVIX, UTERINE/neoplasms